Literature DB >> 22991336

Possible role of interleukin-17 in a prime/challenge model of multiple sclerosis.

Jane E Libbey1, Ikuo Tsunoda, Robert S Fujinami.   

Abstract

No one single pathogen has been identified as the causative agent of multiple sclerosis (MS). Alternately, the likelihood of an autoimmune event may be nonspecifically enhanced by different infectious agents. In a novel animal model of MS, SJL/J mice primed through infection with a recombinant vaccinia virus (VV) encoding myelin proteolipid protein (PLP) (VV(PLP)) were susceptible to a central nervous system (CNS) inflammatory disease following administration of a nonspecific immunostimulant [complete Freund's adjuvant (CFA) plus Bordetella pertussis (BP)]. Mononuclear cells isolated from the brains, but not the spleens, of VV(PLP)-primed CFA/BP challenged mice produced interleukin (IL)-17 and interferon-γ and transferred a CNS inflammatory disease to naïve SJL/J mice. Administration of curdlan, a T helper 17 cell inducer, unexpectedly resulted in less severe clinical and histological signs of disease, compared to CFA/BP challenged mice, despite the induction of IL-17 in the periphery. Further examination of the VV(PLP)-prime CFA/BP challenge model may suggest new mechanisms for how different pathogens associated with MS can protect or enhance disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22991336      PMCID: PMC3508306          DOI: 10.1007/s13365-012-0125-y

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


  32 in total

Review 1.  The case for rhinoviruses in the pathogenesis of multiple sclerosis.

Authors:  John D Kriesel; William A Sibley
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

2.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

3.  Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA.

Authors:  I Tsunoda; L Q Kuang; N D Tolley; J L Whitton; R S Fujinami
Journal:  J Neuropathol Exp Neurol       Date:  1998-08       Impact factor: 3.685

Review 4.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 5.  Th17 cell, the new player of neuroinflammatory process in multiple sclerosis.

Authors:  F Jadidi-Niaragh; A Mirshafiey
Journal:  Scand J Immunol       Date:  2011-07       Impact factor: 3.487

Review 6.  Cytokines and effector T cell subsets causing autoimmune CNS disease.

Authors:  Franziska Petermann; Thomas Korn
Journal:  FEBS Lett       Date:  2011-04-06       Impact factor: 4.124

7.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

8.  Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-07-02       Impact factor: 3.478

Review 9.  Molecular mimicry as a mechanism of autoimmune disease.

Authors:  Matthew F Cusick; Jane E Libbey; Robert S Fujinami
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 10.  Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

Authors:  Shyi-Jou Chen; Yen-Ling Wang; Hueng-Chuen Fan; Wen-Tsung Lo; Chih-Chien Wang; Huey-Kang Sytwu
Journal:  Clin Dev Immunol       Date:  2011-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.